Developer docs
API playgroundTry for free, no card

Search company profiles

ViruSure

Full company profile

uuid0006m4f

Namestring
ViruSure
Legal namestring
ViruSure Forschung und Entwicklung GmbH
Websiteurl
virusure.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

ViruSure is an Austrian Contract Research Organization (CRO) founded in 2005 by Dr. Andy Bailey as a spin-off from the University of Veterinary Medicine Vienna, specializing in virus and prion safety testing for biopharmaceutical products. The company operates from a GMP/GLP-certified facility at the Tech Gate Science and Technology Park in Vienna and has been a wholly owned subsidiary of Asahi Kasei Medical Co., Ltd. since 2019, sitting within its Bioprocess Division alongside sister companies Bionique Testing Laboratories and Bionova Scientific. ViruSure has performed over 600 viral clearance studies across 17+ years and is the only provider of in vivo prion bioassay in Europe — the gold-standard assay for claiming prion safety margins.

The company's service portfolio spans viral clearance studies, prion clearance studies (including the proprietary Western blot assay developed by Dr. Bailey), GMP biosafety studies (in vitro, in vivo, molecular, tumorigenicity/oncogenicity), GMP lot release testing, cell and virus banking, Next-Generation Sequencing using Oxford Nanopore long-read technology (MinION and PromethION), GMP-compliant Transmission Electron Microscopy, and consultancy services covering molecular biology, virus safety strategy, BSE/TSE risk assessments, GMP inspection readiness, cell therapy CMC readiness, and cultured meat innovation. In March 2026, ViruSure and Oxford Nanopore Technologies launched the world's first GMP-validated adventitious viral agent detection test based on long-read sequencing, consolidating multiple legacy assays into a single GMP-compliant workflow.

ViruSure generates revenue through project-based, fee-for-service contracts with biopharmaceutical clients globally, with quote-based pricing that is not publicly disclosed. Customer segments include developers of recombinant products, monoclonal antibodies, Advanced Therapy Medicinal Products (cell and gene therapies), vaccines, plasma- and urine-derived protein products, animal-derived tissue products, and — as an emerging vertical — cell-cultured meat companies. Go-to-market is enterprise field sales with direct engagement, supported by regional representatives in Korea (Young Sciences, Inc.) and Japan (LunaPath), and the company holds PMDA accreditation as a foreign manufacturer to serve Japanese biopharma clients.

Short descriptiontext

ViruSure is an Austrian GMP/GLP-certified CRO providing virus and prion safety testing — viral and prion clearance studies, NGS, TEM, and biosafety consultancy — to biopharmaceutical developers of recombinant products, ATMPs, vaccines, and plasma-derived therapeutics, with over 600 studies completed across 17+ years.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVienna, Austria
HQ citystring
Vienna
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosafety testing services, viral clearance studies, prion safety testing, biopharmaceutical contract research, GMP testing services
Industry4 codes
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAAAJAL
Viral Clearance, Sterile Filtration & Bioburden Control Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biosafety Testing Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Organization (CRO) Services
TypeProfessional Services
Description

ViruSure generates revenue as a CRO providing fee-for-service biosafety testing. Services include viral clearance studies, prion clearance studies, GMP/GLP biosafety studies, cell and virus banking services, molecular testing, TEM, NGS, and consultancy services. Revenue is project-based, typically charged per study or test conducted for biopharmaceutical clients.

virusure.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ViruSure is a Contract Research Organization (CRO) that performs GLP/GMP-compliant biosafety testing services for biopharmaceutical manufacturers. Its core service portfolio covers viral clearance studies, prion clearance studies, GMP biosafety studies (in vitro, in vivo, molecular, TEM, tumorigenicity, lot release), next-generation sequencing, transmission electron microscopy, cell and virus banking, and a range of regulatory consultancies. Services target manufacturers of recombinant products, vaccines, ATMPs, plasma/urine-derived proteins, animal-derived tissue products, and cell-cultured meat.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First GMP-validated adventitious viral agent detection test based on Oxford Nanopore sequencing consolidates multiple assays into a single test, potentially reducing testing timelines by weeks
+1 more record
Product overview1 text field

ViruSure is a Contract Research Organization (CRO) providing biosafety testing services as a single unified offering rather than a software platform. The core portfolio consists of testing services organized around viral and prion safety, including Viral Clearance Studies (600+ successful studies), Prion Clearance Studies (including the only in vivo prion bioassay in Europe), GMP Biosafety Studies (in vitro, in vivo, molecular, TEM), and GMP/GLP Characterization (genetic stability, neutralization studies, biodistribution). Supporting services include Next-Generation Sequencing using Oxford Nanopore technology, Transmission Electron Microscopy, Cell and Virus Banking Services, and consultancies covering Molecular Biology, Virus Safety, BSE Expertise, Inspection Readiness, Cell Therapy CMC Readiness, and Cultured Meat Innovation. The company also launched the first GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore sequencing in March 2026. Testing services cover recombinant products, plasma/urine-derived proteins, vaccines, ATMPs (gene/cell therapy), animal-derived products, and cell-cultured meat products.

Product and service15 records
1GMP-Validated AVA Detection Test (Oxford Nanopore Sequencing)
CategoryViral Safety Testing
Description

First-in-class GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore long-read sequencing for biopharmaceutical quality control. Consolidates multiple assays into a single test, reducing testing timelines by weeks and simplifying GMP-regulated laboratory workflows while reducing false positives that can trigger costly manufacturing pauses.

2Viral Clearance Studies
CategoryVirus/Prion Clearance Studies
Description

GLP and non-GLP viral clearance studies evaluating a biopharmaceutical product's manufacturing process ability to remove or inactivate viral agents, essential prior to clinical trials. Includes consultancy on study design. Over 600 successful studies performed across a wide range of biopharmaceutical products.

3Prion Clearance Studies
CategoryVirus/Prion Clearance Studies
Description

Investigational prion safety studies including the only in vivo prion bioassay available in Europe - the gold standard for claiming prion safety margins. Services include TSE model studies, Western blot testing for prion protein (first commercially available), and in vivo prion bioassays using rodent-adapted prion strains.

4GMP Biosafety Studies
CategoryGMP Biosafety Testing
Description

GMP-compliant biosafety testing including in vitro safety studies, molecular tests, transmission electron microscopy, in vivo safety studies, tumorigenicity and oncogenicity studies, and GMP lot release testing for bulk harvests.

5Next-Generation Sequencing (NGS)
CategoryMolecular Testing
Description

GMP-compliant NGS testing for genetic characterization (genetic stability, sequence identity, cell line identity) and adventitious agent detection using Oxford Nanopore long-read sequencing technology with MinION and PromethION devices, achieving over 99% accuracy.

6Transmission Electron Microscopy (TEM)
CategoryMolecular Testing
Description

GMP-compliant TEM testing for adventitious agents, RVLPs, virus characterization, and AAV analysis using negative stain TEM, positive stain TEM, and cryoTEM techniques. Includes determination of capsid particle population, assessment of capsid integrity and purity, and distinguishing between full-empty capsid ratios, with low sample requirements (2 µL, 1×10^11 vp/mL).

7Cell and Virus Banking Services
CategoryCell and Virus Banking
Description

GMP cell and virus banking services including characterization, storage, and sterility and mycoplasma testing for biopharmaceutical production.

8GMP/GLP Characterization
CategoryGMP/GLP Characterization
Description

Characterization studies including genetic stability testing, neutralization studies, virus permissivity studies, and biodistribution studies for ATMPs.

9Molecular Biology Consultancy
CategoryConsultancy and Risk Assessments
Description

Expert consultancy for molecular biology applications, experiment design, and data interpretation using NGS, qPCR, dPCR, and Sanger sequencing technologies.

10Virus Safety Consultancy
CategoryConsultancy and Risk Assessments
Description

Comprehensive virus safety strategy development including donor testing, process evaluation for virus removal, virus validation for continuous manufacturing, and regulatory guidance.

11BSE/TSE Risk Assessment Consultancy
CategoryConsultancy and Risk Assessments
Description

Expert consultancy for BSE and TSE risk management including biosafety evaluation, CTD 3.2.A.2 documentation, epidemiology assessment, prion clearance capacity evaluation, and prion safety assessments.

12Inspection Readiness Consultancy
CategoryConsultancy and Risk Assessments
Description

GMP inspection readiness consultancy including mock inspections, gap analysis, sterility assurance, and contamination control strategy development aligned with GMP Annex 1 requirements.

13Cell Therapy CMC Readiness Consultancy
CategoryConsultancy and Risk Assessments
Description

Consultancy for cell therapy Chemistry, Manufacturing, and Controls readiness including mycoplasma testing guidance, regulatory navigation, virus clearance study design for AAVs, and virus safety risk assessments.

14Cultured Meat Innovation Consultancy
CategoryConsultancy and Risk Assessments
Description

Specialized consultancy for cultured meat products including cell culture optimization, donor animal risk assessments, TSE risk assessments, sterility testing, and mycoplasma testing.

15Disinfectant Testing
CategoryOther Services
Description

Virucidal efficacy testing of disinfectants following DIN, Robert Koch Institute (RKI), and German Association for the Control of Virus Diseases (DVV) guidelines.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-10
Description

ViruSure collaborated with Oxford Nanopore Technologies to launch the world's first GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore sequencing for biopharmaceutical quality control. The solution consolidates multiple assays into a single test, reducing testing timelines and simplifying GMP-regulated workflows. ViruSure is an Oxford Nanopore certified service provider, operating MinION and high-throughput PromethION devices. The partnership progressed from GLP validation in August 2025 to GMP validation, demonstrating regulatory readiness for commercial biologics manufacturing.

2neotem Bioanalytics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-10
Description

ViruSure partnered with neotem Bioanalytics, a specialist in GMP-compliant electron microscopy analysis with over 40 years of combined experience in electron microscopy, virology, and quality assurance. The collaboration addresses bottlenecks for high-quality and rapid TEM analysis, enabling improved timelines for pathogen safety testing. neotem provides GMP-compliant TEM analysis for cell banks, virus banks, bulk harvests, and AAV testing, while ViruSure supports neotem in enhancing their quality system to achieve state-of-the-art GMP-compliant services.

virusure.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-04-19
Description

Bionova Scientific, LLC was acquired by Asahi Kasei Medical and operates as a sister company to ViruSure. Bionova Scientific is a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies. The acquisition represents a strategic complementary addition to strengthen Asahi Kasei Medical's bioprocess business and US market presence.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-16
Description

Bionique Testing Laboratories LLC was acquired by Asahi Kasei Medical and joined ViruSure as a sister company within the global biosafety testing services unit of Asahi Kasei Medical's Bioprocess Division. Bionique specializes in mycoplasma testing services for biologics and life sciences. The acquisition brings together the unique mycoplasma and viral safety proficiencies of both companies, enabling comprehensive biosafety testing support. Both companies continue operations under their existing brands.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Broad bioprocess vendor that has expanded into biosafety and viral clearance services through acquisitions, competing for the same gene-therapy and ATMP safety testing work as ViruSure.

TypeDirect peer
Description

Specialist virology CRO providing viral clearance studies, biosafety testing, and viral vector characterization — a close niche competitor in virus safety testing for biopharma.

TypeDirect peer
Description

Large global CRO with a Biologics Testing Solutions segment that provides viral clearance, biosafety, and cell banking services for biopharmaceutical clients — directly overlapping ViruSure's core offering.

TypeDirect peer
Description

Provides GMP/GLP laboratory testing including viral clearance, biocompatibility, and extractables/leachables, with significant overlap to ViruSure's biosafety testing portfolio.

TypeDirect peer
Description

Global CRO offering biosafety, viral clearance, and cell bank characterization services across multiple continents; competes for the same biopharma safety-testing RFPs as ViruSure.

TypeDirect peer
Description

Sister company under Asahi Kasei Medical specializing in mycoplasma testing for biologics; provides overlapping biosafety testing services to the same client base as ViruSure.

7Vironova (part of BioTek Labs)
TypeEmerging player
Description

Specialist in transmission electron microscopy for viral vectors and gene therapy products — overlapping with ViruSure's GMP TEM and AAV characterization services.

8BioReliance (Merck/Sigma-Aldrich Biopharma Services)
TypeDirect peer
Description

Provides biosafety testing, viral clearance, and raw material testing for biologics and gene therapies under Merck's Life Science Services arm, overlapping heavily with ViruSure.

9WuXi AppTec (WuXi Biologics / Testing Division)
TypeBroad incumbent
Description

Global CRO/CDMO with biosafety testing capabilities bundled into a much larger biologics services portfolio; competes on scale and integrated offering rather than specialization.

TypeBroad incumbent
Description

Global testing, inspection, and certification company offering biosafety, viral clearance, and cell bank characterization as part of a much broader life sciences services portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ViruSure

Biosafety Testing Servicesvirusure.com

ViruSure is an Austrian GMP/GLP-certified CRO providing virus and prion safety testing — viral and prion clearance studies, NGS, TEM, and biosafety consultancy — to biopharmaceutical developers of recombinant products, ATMPs, vaccines, and plasma-derived therapeutics, with over 600 studies completed across 17+ years.

What ViruSure does

ViruSure is an Austrian Contract Research Organization (CRO) founded in 2005 by Dr. Andy Bailey as a spin-off from the University of Veterinary Medicine Vienna, specializing in virus and prion safety testing for biopharmaceutical products. The company operates from a GMP/GLP-certified facility at the Tech Gate Science and Technology Park in Vienna and has been a wholly owned subsidiary of Asahi Kasei Medical Co., Ltd. since 2019, sitting within its Bioprocess Division alongside sister companies Bionique Testing Laboratories and Bionova Scientific. ViruSure has performed over 600 viral clearance studies across 17+ years and is the only provider of in vivo prion bioassay in Europe — the gold-standard assay for claiming prion safety margins.

The company's service portfolio spans viral clearance studies, prion clearance studies (including the proprietary Western blot assay developed by Dr. Bailey), GMP biosafety studies (in vitro, in vivo, molecular, tumorigenicity/oncogenicity), GMP lot release testing, cell and virus banking, Next-Generation Sequencing using Oxford Nanopore long-read technology (MinION and PromethION), GMP-compliant Transmission Electron Microscopy, and consultancy services covering molecular biology, virus safety strategy, BSE/TSE risk assessments, GMP inspection readiness, cell therapy CMC readiness, and cultured meat innovation. In March 2026, ViruSure and Oxford Nanopore Technologies launched the world's first GMP-validated adventitious viral agent detection test based on long-read sequencing, consolidating multiple legacy assays into a single GMP-compliant workflow.

ViruSure generates revenue through project-based, fee-for-service contracts with biopharmaceutical clients globally, with quote-based pricing that is not publicly disclosed. Customer segments include developers of recombinant products, monoclonal antibodies, Advanced Therapy Medicinal Products (cell and gene therapies), vaccines, plasma- and urine-derived protein products, animal-derived tissue products, and — as an emerging vertical — cell-cultured meat companies. Go-to-market is enterprise field sales with direct engagement, supported by regional representatives in Korea (Young Sciences, Inc.) and Japan (LunaPath), and the company holds PMDA accreditation as a foreign manufacturer to serve Japanese biopharma clients.

ViruSure firmographics

Firmographics
Name
ViruSure
Legal name
ViruSure Forschung und Entwicklung GmbH
Website
https://virusure.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
ViruSure is an Austrian GMP/GLP-certified CRO providing virus and prion safety testing — viral and prion clearance studies, NGS, TEM, and biosafety consultancy — to biopharmaceutical developers of recombinant products, ATMPs, vaccines, and plasma-derived therapeutics, with over 600 studies completed across 17+ years.
Ownership category
akta.pro rank

ViruSure industry classification

Industry
Product category
Biosafety Testing Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAAAJAL
Viral Clearance, Sterile Filtration & Bioburden Control Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Biosafety testing services
  • Viral clearance studies
  • Prion safety testing
  • Biopharmaceutical contract research
  • GMP testing services

Where ViruSure is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
Austria
HQ region
Europe

Offices3 records

Markets served

ViruSure business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Organization (CRO) Services: ViruSure generates revenue as a CRO providing fee-for-service biosafety testing. Services include viral clearance studies, prion clearance studies, GMP/GLP biosafety studies, cell and virus banking services, molecular testing, TEM, NGS, and consultancy services. Revenue is project-based, typically charged per study or test conducted for biopharmaceutical clients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

ViruSure product offering

Product offering

Core offering

ViruSure is a Contract Research Organization (CRO) that performs GLP/GMP-compliant biosafety testing services for biopharmaceutical manufacturers. Its core service portfolio covers viral clearance studies, prion clearance studies, GMP biosafety studies (in vitro, in vivo, molecular, TEM, tumorigenicity, lot release), next-generation sequencing, transmission electron microscopy, cell and virus banking, and a range of regulatory consultancies. Services target manufacturers of recombinant products, vaccines, ATMPs, plasma/urine-derived proteins, animal-derived tissue products, and cell-cultured meat.

Product overview

ViruSure is a Contract Research Organization (CRO) providing biosafety testing services as a single unified offering rather than a software platform. The core portfolio consists of testing services organized around viral and prion safety, including Viral Clearance Studies (600+ successful studies), Prion Clearance Studies (including the only in vivo prion bioassay in Europe), GMP Biosafety Studies (in vitro, in vivo, molecular, TEM), and GMP/GLP Characterization (genetic stability, neutralization studies, biodistribution). Supporting services include Next-Generation Sequencing using Oxford Nanopore technology, Transmission Electron Microscopy, Cell and Virus Banking Services, and consultancies covering Molecular Biology, Virus Safety, BSE Expertise, Inspection Readiness, Cell Therapy CMC Readiness, and Cultured Meat Innovation. The company also launched the first GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore sequencing in March 2026. Testing services cover recombinant products, plasma/urine-derived proteins, vaccines, ATMPs (gene/cell therapy), animal-derived products, and cell-cultured meat products.

Differentiator

Problem solved

Functional benefit

Products and services

  • GMP-Validated AVA Detection Test (Oxford Nanopore Sequencing) First-in-class GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore long-read sequencing for biopharmaceutical quality control. Consolidates multiple assays into a single test, reducing testing timelines by weeks and simplifying GMP-regulated laboratory workflows while reducing false positives that can trigger costly manufacturing pauses.
  • Viral Clearance Studies GLP and non-GLP viral clearance studies evaluating a biopharmaceutical product's manufacturing process ability to remove or inactivate viral agents, essential prior to clinical trials. Includes consultancy on study design. Over 600 successful studies performed across a wide range of biopharmaceutical products.
  • Prion Clearance Studies Investigational prion safety studies including the only in vivo prion bioassay available in Europe - the gold standard for claiming prion safety margins. Services include TSE model studies, Western blot testing for prion protein (first commercially available), and in vivo prion bioassays using rodent-adapted prion strains.
  • GMP Biosafety Studies GMP-compliant biosafety testing including in vitro safety studies, molecular tests, transmission electron microscopy, in vivo safety studies, tumorigenicity and oncogenicity studies, and GMP lot release testing for bulk harvests.
  • Next-Generation Sequencing (NGS) GMP-compliant NGS testing for genetic characterization (genetic stability, sequence identity, cell line identity) and adventitious agent detection using Oxford Nanopore long-read sequencing technology with MinION and PromethION devices, achieving over 99% accuracy.
  • Transmission Electron Microscopy (TEM) GMP-compliant TEM testing for adventitious agents, RVLPs, virus characterization, and AAV analysis using negative stain TEM, positive stain TEM, and cryoTEM techniques. Includes determination of capsid particle population, assessment of capsid integrity and purity, and distinguishing between full-empty capsid ratios, with low sample requirements (2 µL, 1×10^11 vp/mL).
  • Cell and Virus Banking Services GMP cell and virus banking services including characterization, storage, and sterility and mycoplasma testing for biopharmaceutical production.
  • GMP/GLP Characterization Characterization studies including genetic stability testing, neutralization studies, virus permissivity studies, and biodistribution studies for ATMPs.
  • Molecular Biology Consultancy Expert consultancy for molecular biology applications, experiment design, and data interpretation using NGS, qPCR, dPCR, and Sanger sequencing technologies.
  • Virus Safety Consultancy Comprehensive virus safety strategy development including donor testing, process evaluation for virus removal, virus validation for continuous manufacturing, and regulatory guidance.
  • BSE/TSE Risk Assessment Consultancy Expert consultancy for BSE and TSE risk management including biosafety evaluation, CTD 3.2.A.2 documentation, epidemiology assessment, prion clearance capacity evaluation, and prion safety assessments.
  • Inspection Readiness Consultancy GMP inspection readiness consultancy including mock inspections, gap analysis, sterility assurance, and contamination control strategy development aligned with GMP Annex 1 requirements.
  • Cell Therapy CMC Readiness Consultancy Consultancy for cell therapy Chemistry, Manufacturing, and Controls readiness including mycoplasma testing guidance, regulatory navigation, virus clearance study design for AAVs, and virus safety risk assessments.
  • Cultured Meat Innovation Consultancy Specialized consultancy for cultured meat products including cell culture optimization, donor animal risk assessments, TSE risk assessments, sterility testing, and mycoplasma testing.
  • Disinfectant Testing Virucidal efficacy testing of disinfectants following DIN, Robert Koch Institute (RKI), and German Association for the Control of Virus Diseases (DVV) guidelines.

Quantifiable outcome

  • First GMP-validated adventitious viral agent detection test based on Oxford Nanopore sequencing consolidates multiple assays into a single test, potentially reducing testing timelines by weeks
  • +1 more outcomes

Companies that use ViruSure

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles5 records

ViruSure technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

ViruSure partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Oxford Nanopore TechnologiescoreTechnology or Integration · 10 March 2026ViruSure collaborated with Oxford Nanopore Technologies to launch the world's first GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore sequencing for biopharmaceutical quality control. The solution consolidates multiple assays into a single test, reducing testing timelines and simplifying GMP-regulated workflows. ViruSure is an Oxford Nanopore certified service provider, operating MinION and high-throughput PromethION devices. The partnership progressed from GLP validation in August 2025 to GMP validation, demonstrating regulatory readiness for commercial biologics manufacturing.
  • neotem BioanalyticscoreStrategic or Co-development Partner · 10 April 2024ViruSure partnered with neotem Bioanalytics, a specialist in GMP-compliant electron microscopy analysis with over 40 years of combined experience in electron microscopy, virology, and quality assurance. The collaboration addresses bottlenecks for high-quality and rapid TEM analysis, enabling improved timelines for pathogen safety testing. neotem provides GMP-compliant TEM analysis for cell banks, virus banks, bulk harvests, and AAV testing, while ViruSure supports neotem in enhancing their quality system to achieve state-of-the-art GMP-compliant services.
  • Bionova Scientific, LLCminorStrategic or Co-development Partner · 19 April 2022Bionova Scientific, LLC was acquired by Asahi Kasei Medical and operates as a sister company to ViruSure. Bionova Scientific is a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies. The acquisition represents a strategic complementary addition to strengthen Asahi Kasei Medical's bioprocess business and US market presence.
  • Bionique Testing Laboratories LLCcoreStrategic or Co-development Partner · 16 December 2021Bionique Testing Laboratories LLC was acquired by Asahi Kasei Medical and joined ViruSure as a sister company within the global biosafety testing services unit of Asahi Kasei Medical's Bioprocess Division. Bionique specializes in mycoplasma testing services for biologics and life sciences. The acquisition brings together the unique mycoplasma and viral safety proficiencies of both companies, enabling comprehensive biosafety testing support. Both companies continue operations under their existing brands.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

ViruSure competitors and assessment

Company assessment

Broad incumbents

  • Sartorius (BIA Separations / Analytical Services): Broad bioprocess vendor that has expanded into biosafety and viral clearance services through acquisitions, competing for the same gene-therapy and ATMP safety testing work as ViruSure.
  • WuXi AppTec (WuXi Biologics / Testing Division): Global CRO/CDMO with biosafety testing capabilities bundled into a much larger biologics services portfolio; competes on scale and integrated offering rather than specialization.
  • SGS (Life Sciences / Health & Nutrition): Global testing, inspection, and certification company offering biosafety, viral clearance, and cell bank characterization as part of a much broader life sciences services portfolio.

Direct peers

  • Texcell (Institut für Virusforschung): Specialist virology CRO providing viral clearance studies, biosafety testing, and viral vector characterization — a close niche competitor in virus safety testing for biopharma.
  • Charles River Laboratories: Large global CRO with a Biologics Testing Solutions segment that provides viral clearance, biosafety, and cell banking services for biopharmaceutical clients — directly overlapping ViruSure's core offering.
  • Nelson Labs (Sotera Health): Provides GMP/GLP laboratory testing including viral clearance, biocompatibility, and extractables/leachables, with significant overlap to ViruSure's biosafety testing portfolio.
  • Eurofins Scientific (BioPharma Product Testing): Global CRO offering biosafety, viral clearance, and cell bank characterization services across multiple continents; competes for the same biopharma safety-testing RFPs as ViruSure.
  • Bionique Testing Laboratories: Sister company under Asahi Kasei Medical specializing in mycoplasma testing for biologics; provides overlapping biosafety testing services to the same client base as ViruSure.
  • BioReliance (Merck/Sigma-Aldrich Biopharma Services): Provides biosafety testing, viral clearance, and raw material testing for biologics and gene therapies under Merck's Life Science Services arm, overlapping heavily with ViruSure.

Emerging players

  • Vironova (part of BioTek Labs): Specialist in transmission electron microscopy for viral vectors and gene therapy products — overlapping with ViruSure's GMP TEM and AAV characterization services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

ViruSure social profiles

Digital presence

ViruSure compliance and trust

Trust signal

Compliance6 records

ViruSure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ViruSure leadership team

Management profile

Number of profiles

Profiles8 records

ViruSure funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ViruSure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViruSure

What does ViruSure do?

ViruSure is a Contract Research Organization (CRO) that performs GLP/GMP-compliant biosafety testing services for biopharmaceutical manufacturers. Its core service portfolio covers viral clearance studies, prion clearance studies, GMP biosafety studies (in vitro, in vivo, molecular, TEM, tumorigenicity, lot release), next-generation sequencing, transmission electron microscopy, cell and virus banking, and a range of regulatory consultancies. Services target manufacturers of recombinant products, vaccines, ATMPs, plasma/urine-derived proteins, animal-derived tissue products, and cell-cultured meat.

Is ViruSure a public or private company?

ViruSure is a private company. It is classified as corporate owned and is currently operating.

When was ViruSure founded?

ViruSure was founded in 2005. It employs 51 to 100 people.

Where is ViruSure based?

ViruSure is headquartered in Vienna, Austria, in the Europe region.

How does ViruSure make money?

One revenue line is on record: contract Research Organization (CRO) Services.

Who are ViruSure's main competitors?

Broad incumbents on record are Sartorius (BIA Separations / Analytical Services), WuXi AppTec (WuXi Biologics / Testing Division) and SGS (Life Sciences / Health & Nutrition). Direct peers are Texcell (Institut für Virusforschung), Charles River Laboratories, Nelson Labs (Sotera Health), Eurofins Scientific (BioPharma Product Testing), Bionique Testing Laboratories and BioReliance (Merck/Sigma-Aldrich Biopharma Services). Vironova (part of BioTek Labs) is listed as an emerging player.

Does ViruSure have an API?

No public API is recorded for ViruSure.

What industry is ViruSure in?

ViruSure's product category is Biosafety Testing Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAAAJAL, Viral Clearance, Sterile Filtration & Bioburden Control Technologies. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessCloudOxford Nanopore shares rise under new CEO after company updateOxford Nanopore Technologies, a FTSE 250 DNA sequencing specialist, has appointed Francis Van Parys as its new CEO, replacing founder Gordon Sanghera, after reporting 2025 revenues of £223.9 million, up 22.2% year-on-year, with adjusted EBITDA losses narrowing 31.2% to £86.7m. The company reaffirmed its target to reach adjusted EBITDA breakeven in FY27 and cash flow positive in FY28, while shares rebounded 1.5% to 119p. Oxford Nanopore also announced a collaboration with ViruSure, an Asahi Kasei company, to launch the world's first GMP-validated adventitious viral agent detection test for biopharmaceutical quality control.MorningstarViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore SequencingViruSure, an Asahi Kasei company, announced the launch of the world's first GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore sequencing for use in biopharmaceutical quality control. The first-in-class solution consolidates multiple assays into a single test, potentially reducing testing timelines by weeks and simplifying GMP-regulated laboratory workflows while reducing false positives that can trigger costly manufacturing pauses. The progression from GLP validation (August 2025) to GMP validation marks regulatory readiness for Oxford Nanopore sequencing-based approaches in commercial biologics manufacturing, with the global biosafety testing market valued at approximately £3.2 billion.GlobeNewswireNuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno BiologicsNuvilex announced that cloning of cancer-drug-activating cells for its Phase 3 trials began at Inno Biologics. The cells, previously grown by ViruSure, were thawed and 97% were viable, with testing for adventitious agents. The best clones will be propagated for late-phase pancreatic cancer trials.GlobeNewswireNuvilex Initial Pancreatic Cancer Trial Preparations UnderwayNuvilex signed a contract with ViruSure GmbH to perform initial cell amplification for its pancreatic cancer treatment. The cells will be used in planned clinical trials for advanced, non-surgically removable pancreatic cancer. Nuvilex will fund the contract and continue preparations for the trials.